IMPACT OF ALLERGEN IMMUNOTHERAPY ON QUALITY OF LIFE AND HEALTH CARE COSTS IN ADULTS AND CHILDREN WITH GRASS POLLEN-INDUCED ALLERGIC RHINITIS IN GERMANY
Author(s)
Najib M1, Westerhout KY2, Verheggen B2, Schreder CH3
1Stallergenes, Antony, France, 2Pharmerit International, Rotterdam, The Netherlands, 3Stallergenes GmbH, Kamp-Lintfort, Germany
OBJECTIVES To determine the relative impact of treatment with Oralair®, Grazax®, Alutard® or symptomatic drug treatment (SDT) on clinical effects and healthcare costs in subgroups of adults and children with grass pollen-induced allergic rhinitis (AR) in Germany. The cost-effectiveness of Oralair® has been demonstrated in a mixed population in previous research. METHODS The effects of three years of drug treatment on quality-adjusted life years (QALYs) and associated costs were assessed using a Markov model with a nine-year time horizon. Symptom score data were extracted, and the relative efficacy on QALYs was assessed through a network meta-analysis (i.e. indirect comparison) of placebo-controlled, clinical trial data in adults and children. Patient symptom scores were translated into the impact on quality of life by means of published sources. Costs associated with drug treatment and other healthcare resources, including Statutory Health Insurance payments and patient co-payments, were estimated. The incremental costs and QALYs were generated accordingly. The uncertainty around the model outcomes was determined by means of sensitivity analyses. RESULTS In adults, the analysis predicted more QALYs for Oralair® relative to Grazax®, 0.008 (95%CI: -0.043; 0.062) and Alutard®, 0.028 (95%CI: -0.029; 0.093), combined with incremental costs of -€1,272 (95%CI: -€1,530; -€999) and -€129 (95%CI: -€389; €160) per patient, respectively. Hence, Oralair is dominant relative to Grazax® and Alutard® in adults. The incremental cost-effectiveness ratio was estimated at €15,503 per QALY relative to SDT. Similar results were observed in children, with the exception of Alutard® (lack of data). The sensitivity analyses suggest that results were mostly driven by drug-specific clinical effects on symptom score, drug costs, inputs for immunotherapy discontinuation, and length of the pollen season CONCLUSIONS Oralair® is cost-effective relative to Grazax®, Alutard® and SDT in grass pollen-induced AR in Germany
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PRS56
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders